放疗实践中姑息治疗预后评分(PROPHET)研究:骨转移中预后评分对治疗处方临床影响的调查
该研究在意大利开展全国性调查,通过模拟临床病例问卷评估预后评分(PS,特别是Mizumoto预后评分)对放疗医生骨转移姑息放疗处方决策的影响。结果显示PS使处方转换率出现具有统计学意义的11.12%,转换在住院医师中更高、在预后更差场景亚组中显著更高,并改善了处方一致性及标准处方方式的使用,尤其在预后更差场景。
要点
- PS导致放疗医生处方转换率具有统计学意义的11.12%。
- 处方转换在住院医师中更高,在预后更差场景亚组中显著更高。
- PS改善了放疗医生间处方一致性,尤其预后更差场景亚组。
核心结论
- 据作者所知,PROPHET研究首次直接评估任何PS常规应用的潜在临床后果。
- 根据PROPHET研究,预后评分应整合进骨转移姑息放疗临床实践及放射肿瘤学培训项目。
研究设计与样本
- 在意大利开展全国性调查,评估模拟临床病例的处方决策。
- 从真实临床实践中选取9个临床病例,每个病例描述均包含按PS(特别是Mizumoto预后评分,一种文献中已验证并已在部分临床试验中应用的PS)定义预后分类参数的完整信息。
- 放疗医生通过问卷访谈,每个临床病例均含相同3个问题:详述病例特征但未给出PS预后分类定义后的处方;揭示PS预后分类定义后是否想改变处方;若改变处方则给出新的处方选项。
- 定义三类放疗医生:专职姑息放疗(RO-d)、非专职姑息放疗(RO-nd)和住院培训医师(IT),受访放疗医生分布于全国不同地区。
主要发现
- PS导致放疗医生处方转换率具有统计学意义的11.12%。
- 处方转换在住院医师中更高,在预后更差场景亚组中显著更高。
- PS改善了放疗医生间处方一致性,尤其预后更差场景亚组。
- PS显著增加了标准处方方式,尤其临床表现更差病例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Bone metastases frequently occur during malignant disease. Palliative radiation therapy (PRT) is a crucial part of palliative care because it can relieve pain and improve patients' quality of life. Often, a clinician's survival estimation is too optimistic. Prognostic scores (PSs) can help clinicians tailor PRT indications to avoid over- or undertreatment. Although the PS is supposed to aid radiation oncologists (ROs) in palliative-care scenarios, it is unclear what type of support, and to what extent, could impact daily clinical practice. METHODS AND MATERIALS: A national-based investigation of the prescriptive decisions on simulated clinical cases was performed in Italy. Nine clinical cases from real-world clinical practice were selected for this study. Each case description contained complete information regarding the parameters defining the prognosis class according to the PS (in particular, the Mizumoto Prognostic Score, a validated PS available in literature and already applied in some clinical trials). Each case description contained complete information regarding the parameters defining the prognosis class according to the PS. ROs were interviewed through questionnaires, each comprising the same 3 questions per clinical case, asking (1) the prescription after detailing the clinical case features but not the PS prognostic class definition; (2) whether the RO wanted to change the prescription once the PS prognostic class definition was revealed; and (3) in case of a change of the prescription, a new prescriptive option. Three RO categories were defined: dedicated to PRT (RO-d), nondedicated to PRT (RO-nd), and resident in training (IT). Interviewed ROs were distributed among different regions of the country. RESULTS: Conversion rates, agreements, and prescription trends were investigated. The PS determined a statistically significant 11.12% of prescription conversion among ROs. The conversion was higher for the residents and significantly higher for worse prognostic scenario subgroups, respectively. The PS improved prescriptive agreement among ROs (particularly for worse-prognostic-scenario subgroups). Moreover, PS significantly increased standard prescriptive approaches (particularly for worse-clinical-case presentations). CONCLUSIONS: To the best of our knowledge, the PROPHET study is the first to directly evaluate the potential clinical consequences of the regular application of any PS. According to the Prophet study, a prognostic score should be integrated into the clinical practice of palliative radiation therapy for bone metastasis and training programs in radiation oncology.
引用
- Cellini F, Di Rito A, Siepe G, et al. Prognostic Score in Radiotherapy Practice for Palliative Treatments (PROPHET) Study for Bone Metastases: An Investigation Into the Clinical Effect on Treatment Prescription. Adv Radiat Oncol. 2022. PMID: 36632087. doi:10.1016/j.adro.2022.101134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。